Merck KGaA says Phase III trial of Cilengitide fails

FRANKFURT Mon Feb 25, 2013 1:48am EST

Related Topics

FRANKFURT Feb 25 (Reuters) - Germany's Merck KGaA said a Phase III trial of Cilengitide - a therapy against an aggressive type of brain tumour - did not meet its primary endpoint of significantly increasing overall survival when added to chemoradiotherapy. (Reporting by Marilyn Gerlach)

FILED UNDER: